Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 QTc interval study in healthy adults
NCT07063238Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mk-8527 in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Merck & Co. Primary endpoint: QT interval corrected for heart rate at 24 hours. Started Aug 2025; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07063238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063238.